标题
Semaglutide for the treatment of overweight and obesity: A review
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-10-18
DOI
10.1111/dom.14863
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
- (2022) Takashi Kadowaki et al. Lancet Diabetes & Endocrinology
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
- (2021) Sean Wharton et al. INTERNATIONAL JOURNAL OF OBESITY
- An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight
- (2021) Simone Theilade et al. DIABETES OBESITY & METABOLISM
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- 83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)
- (2021) ILDIKO LINGVAY et al. DIABETES
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excess Body Weight and Gallstone Disease
- (2021) Caroline Sarah Stokes et al. Visceral Medicine
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
- (2021) Sean Wharton et al. POSTGRADUATE MEDICINE
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- How Much Weight Loss is Required for Cardiovascular Benefits? Insights From a Metabolic Surgery Matched-cohort Study
- (2020) Ali Aminian et al. ANNALS OF SURGERY
- Switching between GLP‐1 receptor agonists in clinical practice: expert consensus and practical guidance
- (2020) Akshay B Jain et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Obesity Prevalence in the Long-Term Future in 18 European Countries and in the USA
- (2020) Fanny Janssen et al. Obesity Facts
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- 991-P: Potential of a Novel Long-Acting Glucagon Analog, HM15136, for the Treatment of Obesity
- (2019) JUNG KUK KIM et al. DIABETES
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
- (2019) Michael A. Nauck et al. DIABETES CARE
- Behaviour change, weight loss and remission of Type 2 diabetes: a community‐based prospective cohort study
- (2019) H. Dambha‐Miller et al. DIABETIC MEDICINE
- Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
- (2019) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Maintenance of Lost Weight and Long-Term Management of Obesity
- (2018) Kevin D. Hall et al. MEDICAL CLINICS OF NORTH AMERICA
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Overweight and Obesity Associated with Higher Depression Prevalence in Adults: A Systematic Review and Meta-Analysis
- (2017) Emile Pereira-Miranda et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Management of obesity
- (2016) George A Bray et al. LANCET
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
- (2016) Jean-Luc Faillie et al. JAMA Internal Medicine
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?
- (2015) Donald A. Williamson et al. Obesity
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?
- (2013) M. Y. Donath et al. DIABETES CARE
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Long-Term Persistence of Hormonal Adaptations to Weight Loss
- (2011) Priya Sumithran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-Year Weight Losses in the Look AHEAD Study: Factors Associated With Long-Term Success
- (2011) Thomas A. Wadden et al. Obesity
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Comparison of Strategies for Sustaining Weight LossThe Weight Loss Maintenance Randomized Controlled Trial
- (2008) Laura P. Svetkey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now